The medical sector’s second-quarter earnings have been positive, with companies like Gilead Sciences, Amgen, Regeneron, and Biogen posting strong results and raising guidance for 2025.

Zevra Therapeutics, Inovio Pharmaceuticals, and Journey Medical Corporation are three biotech companies expected to exceed estimates in their upcoming quarterly results.

Zevra Therapeutics has an Earnings ESP of +58.04% and a Zacks Rank #3, with a consensus estimate of $1.43 for second-quarter EPS.

Inovio Pharmaceuticals, with an Earnings ESP of +10.76% and a Zacks Rank #3, is focused on developing DNA medicines for HPV-associated diseases.

Journey Medical Corporation, a pharmaceutical company, markets prescription drugs for dermatological conditions and is set to report second-quarter results on Aug. 12, 2025.

Zacks’ research highlights a stock with the potential to double in value, focusing on a satellite-based communications firm with a growing customer base and projected revenue breakout in 2025.

Read more at Nasdaq: 3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates